{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:25:00Z","timestamp":1791354300463,"version":"4.3.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enzyme and Microbial Technology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.enzmictec.2012.05.005","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T22:19:17Z","timestamp":1337293157000},"page":"67-72","source":"Crossref","is-referenced-by-count":9,"title":["Using recombinant DNA technology for the development of live-attenuated dengue vaccines"],"prefix":"10.1016","volume":"51","author":[{"given":"Hsiang-Chi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suh-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.enzmictec.2012.05.005_bib0005","unstructured":"World Health Organization. Dengue and dengue haemorrhagic fever [online]. http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/2009a."},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0010","unstructured":"World Health Organization. Vector-borne viral infections: dengue fever [online]; 2009. http:\/\/www.who.int\/vaccine_research\/diseases\/vector\/en\/index1.html."},{"issue":"1","key":"10.1016\/j.enzmictec.2012.05.005_bib0015","first-page":"31","article-title":"Recent progress in dengue vaccine research and development","volume":"12","author":"Miller","year":"2010","journal-title":"Current Opinion in Molecular Therapeutics"},{"issue":"Suppl. 4","key":"10.1016\/j.enzmictec.2012.05.005_bib0020","doi-asserted-by":"crossref","first-page":"S830","DOI":"10.1093\/clinids\/11.Supplement_4.S830","article-title":"Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade","volume":"11","author":"Halstead","year":"1989","journal-title":"Reviews of Infectious Diseases"},{"issue":"3","key":"10.1016\/j.enzmictec.2012.05.005_bib0025","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"1","key":"10.1016\/j.enzmictec.2012.05.005_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-1702(98)00036-7","article-title":"Yellow fever 17D vaccine virus isolated from healthy vaccines accumulates very few mutations","volume":"55","author":"Xie","year":"1998","journal-title":"Virus Research"},{"issue":"1","key":"10.1016\/j.enzmictec.2012.05.005_bib0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"Suppl. 6","key":"10.1016\/j.enzmictec.2012.05.005_bib0040","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690005","article-title":"Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii","volume":"69","author":"Halstead","year":"2003","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"7","key":"10.1016\/j.enzmictec.2012.05.005_bib0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nature Reviews Microbiology"},{"issue":"Suppl. 2","key":"10.1016\/j.enzmictec.2012.05.005_bib0050","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0264-410X(00)00040-2","article-title":"Live attenuated tetravalent dengue vaccine","volume":"18","author":"Bhamarapravati","year":"2000","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.enzmictec.2012.05.005_bib0055","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1016\/j.enzmictec.2012.05.005_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Suppl. 6","key":"10.1016\/j.enzmictec.2012.05.005_bib0065","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"Suppl. 6","key":"10.1016\/j.enzmictec.2012.05.005_bib0070","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.4269\/ajtmh.2003.69.17","article-title":"Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines","volume":"69","author":"Kanesa-Thasan","year":"2003","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"Suppl. 6","key":"10.1016\/j.enzmictec.2012.05.005_bib0075","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1006\/viro.1997.8500","article-title":"Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53","volume":"230","author":"Kinney","year":"1997","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.enzmictec.2012.05.005_bib0085","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1073\/pnas.88.12.5139","article-title":"Infectious RNA transcribed from stably cloned full length cDNA of dengue type 4 virus","volume":"88","author":"Lai","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0090","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3\u2019noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0928-0197(98)00035-X","article-title":"Evaluation of molecular strategies to develop a live dengue vaccine","volume":"10","author":"Lai","year":"1998","journal-title":"Clinical and Diagnostic Virology"},{"issue":"21","key":"10.1016\/j.enzmictec.2012.05.005_bib0100","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"77","author":"Huang","year":"2003","journal-title":"Journal of Virology"},{"issue":"5","key":"10.1016\/j.enzmictec.2012.05.005_bib0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2032-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"12","key":"10.1016\/j.enzmictec.2012.05.005_bib0110","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0115","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JVI.75.16.7290-7304.2001","article-title":"Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine","volume":"75","author":"Guirakhoo","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.enzmictec.2012.05.005_bib0125","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0130","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1371\/journal.pone.0001810","article-title":"High genetic stability of dengue virus propagated in MRC-5 cells as compared to the virus propagated in vero cells","volume":"3","author":"Liu","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0135","doi-asserted-by":"crossref","first-page":"e25800","DOI":"10.1371\/journal.pone.0025800","article-title":"Dengue type 4 live-attenuated vaccine viruses passaged in Vero cells affect genetic stability and dengue-induced hemorrhaging in mice","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0140","first-page":"1182","article-title":"Viral vaccine production in cell culture","volume":"vol. 2","author":"Aunins","year":"2000"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/viro.2002.1528","article-title":"Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells","volume":"300","author":"Blaney","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0150","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1016\/S0264-410X(03)00487-0","article-title":"Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2\/4 vaccine candidate in Vero cells","volume":"21","author":"Blaney","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0155","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccines for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"issue":"November (Suppl. 3)","key":"10.1016\/j.enzmictec.2012.05.005_bib0160","first-page":"S363","article-title":"Dengue vaccine","volume":"88","author":"Simasathien","year":"2005","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"Suppl. 2","key":"10.1016\/j.enzmictec.2012.05.005_bib0165","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1386-6532(09)70291-4","article-title":"Recent progress on Sanofi Pasteur's dengue vaccine candidate","volume":"46","author":"Lang","year":"2009","journal-title":"Journal of Clinical Virology"},{"issue":"3","key":"10.1016\/j.enzmictec.2012.05.005_bib0170","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirusnaive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"Journal of Infectious Diseases"},{"issue":"2\u20133","key":"10.1016\/j.enzmictec.2012.05.005_bib0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cimid.2007.07.011","article-title":"Towards a dengue vaccine: progress to date and remaining challenges","volume":"31","author":"Guy","year":"2008","journal-title":"Comparative Immunology, Microbiology and Infectious Diseases"},{"issue":"2","key":"10.1016\/j.enzmictec.2012.05.005_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Human Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.enzmictec.2012.05.005_bib0185","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1386-6532(09)70290-2","article-title":"Immunogenicity of Sanofi Pasteur tetravalent dengue vaccine","volume":"46","author":"Guy","year":"2009","journal-title":"Journal of Clinical Virology"},{"issue":"42","key":"10.1016\/j.enzmictec.2012.05.005_bib0190","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0195","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immuongenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0200","series-title":"4th Asian dengue research network meeting","first-page":"42","article-title":"Clinical and preclinical evaluation of DENVax, a tetravalent DEN-2 PDK-53-based chimeric dengue vaccine","author":"Osorio","year":"2009"},{"issue":"6","key":"10.1016\/j.enzmictec.2012.05.005_bib0205","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2032-UTR) or by exchange of the DENV-3 3\u2032-UTR with that of DENV-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.enzmictec.2012.05.005_bib0210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2032 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0215","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1128\/JVI.75.20.9731-9740.2001","article-title":"Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice","volume":"75","author":"Blaney","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0220","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/JVI.76.2.525-531.2002","article-title":"Whitehead SS. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes","volume":"76","author":"Hanley","year":"2002","journal-title":"Journal of Virology"},{"issue":"22","key":"10.1016\/j.enzmictec.2012.05.005_bib0225","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/j.vaccine.2004.02.031","article-title":"Introduction of mutations into the non-structural genes or 3\u2019 untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity","volume":"3","author":"Hanley","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0230","series-title":"Third Asian Regional Dengue Research Network Meeting","first-page":"p. 58","article-title":"Development of dengue 2-PDK-53-based chimeric tetravalent dengue vaccines","author":"Stinchcomb","year":"2007"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0235","doi-asserted-by":"crossref","first-page":"10384","DOI":"10.1128\/JVI.01083-09","article-title":"Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in Rhesus Macaques","volume":"83","author":"Anez","year":"2009","journal-title":"Journal of Virology"},{"issue":"2","key":"10.1016\/j.enzmictec.2012.05.005_bib0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2005.07.067","article-title":"Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys","volume":"24","author":"Rumyantsev","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.enzmictec.2012.05.005_bib0245","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/vbz.2010.0179","article-title":"Chimeric tick-borne encephalitis\/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes","volume":"11","author":"Engel","year":"2011","journal-title":"Vector Borne and Zoonotic Diseases"},{"issue":"8","key":"10.1016\/j.enzmictec.2012.05.005_bib0250","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"15","author":"Monath","year":"2003","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1016\/j.enzmictec.2012.05.005_bib0255","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV(\u00ae): a yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Review of Vaccines"},{"issue":"17","key":"10.1016\/j.enzmictec.2012.05.005_bib0260","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.enzmictec.2012.05.005_bib0265","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/jiq074","article-title":"Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination","volume":"15","author":"Smith","year":"2011","journal-title":"Journal of Infectious Diseases"},{"issue":"11","key":"10.1016\/j.enzmictec.2012.05.005_bib0270","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"23","author":"Hoffmann","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0275","first-page":"313","article-title":"Influenza vaccines generated by reverse genetics","volume":"283","author":"Subbarao","year":"2004","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"36","key":"10.1016\/j.enzmictec.2012.05.005_bib0280","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"Karron","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2012.02.064","article-title":"Cost of production of live attenuated dengue vaccine: A case study of the Instituto Butantan, Sao Paulo, Brazil","author":"Mahoney","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0290","unstructured":"Inviragen. Inviragen initiates a phase 2 clinical study of DENVax, a recombinant, tetravalent dengue vaccine [online]. http:\/\/www.inviragen.com\/press\/DENVax%20ph2%20initiation%20release%20FINAL.pdf."},{"key":"10.1016\/j.enzmictec.2012.05.005_bib0295","series-title":"XV International Congress of Virology","first-page":"p. 160","article-title":"A recombinant tetravalent live attenuated dengue vaccine based on the 3\u2032-UTR delta-30 mutation is safe and induces a balanced immune response against all 4 serotypes in humans","author":"Whitehead","year":"2011"},{"issue":"November (5)","key":"10.1016\/j.enzmictec.2012.05.005_bib0300","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4269\/ajtmh.2008.79.678","article-title":"Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity","volume":"79","author":"McArthur","year":"2008","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5","key":"10.1016\/j.enzmictec.2012.05.005_bib0305","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4269\/ajtmh.2009.09-0131","article-title":"Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers","volume":"81","author":"Wright","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"}],"container-title":["Enzyme and Microbial Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141022912000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141022912000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T20:32:26Z","timestamp":1594153946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141022912000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0141022912000749"],"URL":"https:\/\/doi.org\/10.1016\/j.enzmictec.2012.05.005","relation":{},"ISSN":["0141-0229"],"issn-type":[{"value":"0141-0229","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}